Plasmapheresis in refractory generalized myasthenia gravis

Area of Science:

• Neurology
• Immunology

Background:

• Myasthenia gravis (MG) is a severe autoimmune disorder affecting neuromuscular junctions.
• Generalized MG refractory to anticholinesterases, thymectomy, and corticosteroids presents a therapeutic challenge.

Purpose of the Study:

• To evaluate the efficacy of plasmapheresis in patients with severe generalized myasthenia gravis resistant to conventional treatments.

Main Methods:

• A cohort of 16 patients with severe generalized MG, including five with thymoma, received plasmapheresis treatment.
• Patients had previously shown resistance to anticholinesterases, thymectomy, and corticosteroids.

Main Results:

• Twelve out of sixteen patients (75%) demonstrated an excellent clinical response to plasmapheresis.
• The positive effects of plasmapheresis were observed to be transient, necessitating repeated treatments.

Conclusions:

• Plasmapheresis is a viable and effective therapeutic option for severe generalized myasthenia gravis unresponsive to other interventions.
• Sustained clinical improvement in refractory myasthenia gravis requires a regimen of periodic plasmapheresis treatments.